<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS: To examine whether high-dose <z:chebi fb="0" ids="35664">statin</z:chebi> therapy in Dutch European patients with Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidaemia</z:e> influenced variables of glycaemic control </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: The CORALL study, which was a 24-week, open-label, randomized, parallel-group, phase IIIb, multi-centre study, was designed to compare the cholesterol-lowering effects of <z:chebi fb="0" ids="38545">rosuvastatin</z:chebi> compared with <z:chebi fb="0" ids="39548">atorvastatin</z:chebi> in patients with Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>Fasting plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> levels and HbA(1c) levels were collected at baseline and at 6 and 18 weeks </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: Treatment with the highest dose of <z:chebi fb="0" ids="35664">statins</z:chebi>, i.e. <z:chebi fb="0" ids="39548">atorvastatin</z:chebi> 80 mg and <z:chebi fb="0" ids="38545">rosuvastatin</z:chebi> 40 mg at 18 weeks from baseline, was associated with increase in HbA(1c) levels; baseline 57 ± 11 mmol/l (7.4 ± 1.0%) to 61 ± 14 mmol/mol (7.7 ± 1.3%) (range 5.0-11.9) for <z:chebi fb="0" ids="39548">atorvastatin</z:chebi> (P = 0.003) and from baseline 60 ± 11 mmol/mol (7.6 ± 1.0%) to 63 ± 13 mmol/mol (7.9 ± 1.2%) (range 5.7-12.3) for <z:chebi fb="0" ids="38545">rosuvastatin</z:chebi> (P &lt; 0.001) </plain></SENT>
<SENT sid="4" pm="."><plain>Mean fasting plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> increased from baseline 8.7 ± 2.4 mmol/l to 9.5 ± 3.0 mmol/l upon treatment with <z:chebi fb="0" ids="39548">atorvastatin</z:chebi> 20 mg (P = 0.002) and 9.0 ± 3.0 mmol/l after treatment with 80 mg (not significant compared with baseline) </plain></SENT>
<SENT sid="5" pm="."><plain>The mean fasting plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> did not change after treatment with <z:chebi fb="0" ids="38545">rosuvastatin</z:chebi> (9.1 ± 2.7 mmol/l at baseline, 8.9 ± 2.7 mmol/l with 10 mg, 9.4 ± 2.9 mmol/l with 40 mg) </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSIONS: Glycaemic control deteriorated in patients with <z:mp ids='MP_0002055'>diabetes</z:mp> following high-dose <z:chebi fb="0" ids="35664">statin</z:chebi> therapy </plain></SENT>
<SENT sid="7" pm="."><plain>Future controlled studies are needed to verify these findings and, if confirmed, determine whether such changes represent a true decline in glycaemic control </plain></SENT>
<SENT sid="8" pm="."><plain>Presently, it appears that, based on the overwhelming prospective trial data available, the preventive effect of <z:chebi fb="0" ids="35664">statin</z:chebi> therapy supersedes that of the slight increase in HbA(1c) </plain></SENT>
</text></document>